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With the rapid increase in resistance to antibiotics, there is a growing need for new tools, as well as new strategies, to treat bacterial infections (1, 2) . Antibiotics such as penicillin, methicillin, and vancomycin all target bacterial cell wall biosynthesis but have either lost or are losing their efficacy (3, 4) . Likewise, in tuberculosis caused by the bacterium Mycobacterium tuberculosis, resistance is on the rise, and new drugs active ideally against new targets are needed. One attractive approach to M. tuberculosis drug discovery is to inhibit isoprenoid biosynthesis enzymes involved in cell wall biosynthesis, in particular, cis-decaprenyl diphosphate synthase (DPPS; Rv2361c), an essential gene for the organism. DPPS converts cis-farnesyl diphosphate (cis-FPP) to cis-decaprenyl diphosphate (cis-DPP, Figure 1 ) in a reaction that is very similar to that catalyzed by undecaprenyl diphosphate synthase (UPPS) in non-mycobacterial systems (such as E. coli and Staphylococcus aureus), where numerous structures and inhibitors are known (5) (6) (7) (8) . Cis-FPP in M. tuberculosis is produced by cis-FPPS (Rv1086c) which is, however, not essential for bacterial cell growth (9) . An implication of this observation is that it would be desirable to inhibit DPPS activity with both GPP as well as cis-FPP as substrates, as we describe here.
Cis-FPPS, cis-DPPS as well as UPPS are proteins that have a f-fold (10), as does the M. tuberculosis enzyme tuberculosinol/tuberculosinyl adenosine synthase (Rv3378c) (11, 12) . Rv3378c is an essential enzyme in persistent, non-replicative M. tuberculosis that resides within macrophages. It was originally thought to be involved in formation of the putative tuberculosinol and iso-tuberculosinol virulence factors (13) , then in formation of edaxadiene (14) and edaxadiene B (15) , and most recently, tuberculosinyl adenosine (12) , and inhibition of Rv3378c is likely to represent a novel anti-virulence approach to therapy (14, 16) . The X-ray crystallographic structures of cis-FPPS (17), cis-DPPS (17), UPPS (6) as well as Rv3378c with bound ligands are all shown in Figure 2 . In UPPS, we previously found (6) that there were up to four inhibitor binding sites (sites 1-4, Figure 2C ), but in cis-FPPS and cis-DPPS, there are far fewer structures and, to date, inhibitors bind only in (or close to) the active site, site 1 (Figure 2A and B) . Likewise, the tuberculosinyl diphosphate substrate for Rv3378c as well as an Rv3378c bisphosphonate inhibitor binds in or near the active site, that is, site 1 in UPPS ( Figure 2D ) (11) .
In this work, we have used molecular dynamics (MD) methods to investigate the structural plasticity of cis-FPPS, cis-DPPS, and Rv3378c and compare the results obtained with those obtained previously for UPPS (18) . Specifically, we investigated the use of X-ray and MD structures to probe prenyl diphosphate chain elongation mechanisms; we screened libraries of small molecules for cis-DPPS inhibition activity; we used both X-ray and MD structures to see to what extent active compounds could be detected in active/decoy libraries; and finally, we investigated the idea that it might be possible to find inhibitors active against all three proteins, cis-FPPS, cis-DPPS, and Rv3378c, of interest as a route to new drug leads targeting both cell wall biosynthesis and virulence.
Methods and Materials

Molecular dynamics simulations
The following cis-FPPS crystal structures were used: apo cis-FPPS (PDB 2VFW), cis-FPPS in complex with trans-FPP (PDB 2VG1), and cis-FPPS in complex with citronellyl diphosphate (CITPP) (PDB 2VG0) (17) . Trans-FPP is a structural analog of the product cis-FPP but has two trans double bonds. For Rv3378c, two dimeric systems based on two different crystal structures were prepared for the MD simulations: apo state (PDB 3WQL) and the inhibitor BPH-629 bound system (PDB 3WQM) (11) . For each system, tleap program in Amber 11 was used to neutralize the systems by adding Na + counterions and solvating using a TIP3P water box (19, 20) . Minimization using the Sander module of Amber 11 was carried out in two stages: 1000 steps of minimization of the solvent and ions with the protein and ligand restrained with a force constant of 500 kcal/mol/ A 2 , followed by a 2500-step minimization of the entire system (21, 22 ). An initial 20-ps MD simulation with a restraint of 10 kcal/mol/ A 2 on the protein and ligand was then performed to heat the system to 300 K. Subsequently, 500-ns MD simulations were carried out on each system under the NPT ensemble at 300 K using Amber 11 with the ff99SBildn force field (21) (22) (23) . Periodic boundary conditions were used, along with a non-bonded interaction cutoff of 10 A for particle mesh Ewald (PME) longrange electrostatic interaction calculations. Bonds involving hydrogen atoms were constrained using the SHAKE algorithm, allowing for a time step of 2 fs (24).
For DPPS, we used the following structures: apo DPPS (PDB 2VG4), DPPS in complex with IPP bound to monomer B (PDB 2VG2), and DPPS in complex with CITPP bound to both monomers (PDB 2VG3) (17) . Glycerol, phosphate, chloride, and sulfate ions used in crystallization were removed from the crystal structures while keeping the magnesium ions, which are essential for catalysis (25) . The protonation states of ionizable amino acid residues were determined using PROPKA and H++ (26) (27) (28) (29) (30) (31) (32) (33) . Ligands were optimized using the B3LYP functional and a 6-31G(d) basis set in Gaussian 03 and parameterized using Antechamber and RESP in Amber Tools 11 with the General AMBER force field (GAFF) (21, (34) (35) (36) . Proteins were solvated with TIP3P water molecules with a buffer region of 10 A in all directions and neutralized with counterions using the tleap program (19, 20) . Each DPPS system was equilibrated using sander with the MPI module of Amber 11 and the ff99SBildn force field (21) (22) (23) . Water molecules were minimized with periodic boundary conditions in a constant volume with the protein and ligands fixed with a force constant of 2.0 kcal/mol/ A 2 , followed by a 150 ps MD simulation in the NPT ensemble. The entire system was minimized and heated from 0 to 300 K over 500 ps, followed by two 20-ps MD simulations in the NVT and NPT ensembles, respectively. Five 500-ns MD simulations were performed on each DPPS system in the NVT ensemble with a Langevin thermostat using the PMEMD module of Amber 11 with the ff99SBildn force field using a graphics card (21) (22) (23) . The PME summation method was used to describe the long-range electrostatic interactions, and short-range non-bonded interactions were truncated at 8 A in the periodic boundary conditions. Volume calculations Active site volumes were calculated using the POVME program with frames extracted every 25 ps from the simulations (37) . Points describing the binding pocket were manually defined along the hydrophobic cavity of monomer B of the apo DPPS structure by locating a sphere with a 1 A diameter at each point, removing any points where van der Waals clashes occurred with the protein. All points defined for monomer B of apo DPPS were used for cis-FPPS as well by aligning the trajectories to monomer B of apo DPPS. Monomer A was also aligned to monomer B so that the results were comparable with the same points defining the active pocket. All ligands simulated in the MD were removed prior to volume calculation. The same procedure was repeated for Rv3378c and the UPPS X-ray crystallographic structures.
Principal component analysis
To compare the results obtained here with previous PCA results on UPPS obtained from 21 X-ray crystallographic structures (7), the X-ray crystal structures of cis-FPPS and DPPS that were used in the MD simulations were projected onto the UPPS PC space. Subsequently, the trajectories of the apo states of cis-FPPS and DPPS were projected onto the UPPS PC space, using the Bio3D package (38) .
Ligand docking
We docked a series of prenyl diphosphates with various chain lengths to cis-FPPS, cis-DPPS, and UPPS using the X-ray crystallographic structures 2VFW, 2VG4, and 2E98, respectively, in addition to the most open conformations taken from the MD simulations. The receptors were prepared by setting the receptor docking grid center to C1 of the cocrystallized ligand (CITPP) in the 2VG3 structure. Self-docking of the ligand CITPP was carried out as a preliminary test of the ability of the receptor grid center to recover the crystallographic pose of the ligand. The size of the inner and outer grid boxes was set to 14 A and 20 A in each direction, respectively. The prenyl diphosphates were then generated with various lengths (from C 10 to C 60 ) with Maestro in Schr€ odinger Suite 2012 a . The molecules were further prepared using LigPrep with the OPLS2005 force field using all possible tautomers and stereoisomers generated in the pH range 5.2 AE 9.2, using Epik b,c (39, 40) . Docking was carried out using Glide XP precision with Glide 5.8
d (41) (42) (43) .
In vitro screening for cis-DPPS, cis-FPPS, and Rv3378c inhibitors
We screened an in-house library of 19 compounds against DPPS using cis-FPP as substrate, 43 compounds using GPP as substrate and 53 compounds using trans-FPP as substrate. The structures and IC 50 values for the active compounds (IC 50 values in the range 31 nM to 880 lM) are shown in Figures S1-S3. DPPS was expressed and purified as described previously (11), as were the DPPS inhibition assays (18) . Briefly, the condensation of IPP and GPP, FPP, or cis-FPP catalyzed by DPPS was monitored using a continuous spectrophotometric assay for diphosphate release (44) in 96-well plates with 200 lL reaction mixtures containing 400 lM 2-amino-6-mercapto-7-methylpurine (MESG), 25 lM GPP, cis-FPP or trans-FPP, 200 lM IPP, 25 mM Tris-HCl (pH 7.5), 0.01% Triton-X-100, and 1 mM MgCl 2 . The IC 50 values were obtained by fitting the inhibition data to a rectangular hyperbolic dose-response function in OriginPro 8.5 (OriginLab, Northampton, MA, USA). The IC 50 values for the most active hits were verified by radiometric assay as follows. A mixture of 15 lM cis-FPP, 100 nM DPPS, and inhibitors in the assay buffer (25 mM Tris-HCl, 1 mM MgCl 2 , 0.01% Triton-X-100) was incubated for 10 min at 25°C. 1.8 lL of 25 lM IPP (1% 1-3 H IPP, 15 lCi/mL, American Radiolabeled Chemicals, Inc.) was then added. The reaction was incubated at 37°C for 10 min before quenching with 500 lL saturated NaCl solution. The saline solution was extracted with 500 lL butanol by vortexing, and 300 lL of the organic layer was transferred into scintillation vial for radiation readout. IC 50 values were fitted in Origin 9.0 by analyzing the doseresponse curves. For cis-FPPS, protein expression, purification, and inhibition were all carried out as reported previously (17) .
For Rv3378c, protein expression and purification were all carried out as reported previously (11) . For inhibition assay of Rv3378c, a mixture of 100 lM TPP, 100 lM adenosine, 75 lg/mL Rv3378c, and inhibitors in the assay buffer (25 mM Tris-HCl, 1 mM MgCl 2 , 0.01% Triton-X-100) was incubated for 2 h at 37°C. Tuberculosinyl adenosine formation was determined by LC/MS carried out using an Agilent LC/MSD Trap XCT Plus instrument. Compounds were separated on a Gemini 3 lm C18 110 A (100*2 mm) column from Phenomenex using a 0-100% methanol (in water with 0.1% formic acid) gradient and monitored using positive-ion mode ESI at m/e = 540.4.
Virtual screening
To incorporate receptor flexibility into computer-aided drug discovery as an application of the relaxed complex scheme, we carried out a virtual screening (VS) of the known actives (Figures S1-S3) against an ensemble of 30 different DPPS conformations (45) . The receptor structures were selected by clustering the apo DPPS trajectory based on the active site volumes. Any potential ligand binding sites in DPPS were first explored using the computational solvent mapping program FTMap, which suggests druggable hot spots in a protein by docking a number of small organic fragments into the protein (46) . Upon evaluating the results of FTMap (see Results and Discussion), we set the receptor grid center as the native binding pocket of the enzyme and used the same protocol as described above for ligand docking for receptor preparation.
The compound libraries consisted of the 43 (GPP substrate), 19 (cis-FPP), or 53 (trans-FPP substrate) experimentally tested active inhibitors with IC 50 s between 0.03 and 20 lM (GPP substrate), 0.6 lM and 90 mM (cis-FPPS substrate), or 0.65 lM and 880 mM (trans-FPP substrate), together with 1000 decoys of average molecular weight 400 Da, from the Glide Decoy Set. The ligands were prepared using LigPrep in Schr€ odinger Suite 2012 with the OPLS2005 force field, and tautomers and stereoisomers were generated within the pH range of 5.2 AE 9.2 using Epik b,c (39, 40) . The VS was carried out with Glide standard precision (SP) using Glide 5.8 d (41) (42) (43) . The VS results were analyzed using the receiver operating characteristic (ROC) and the area under the curve (AUC) metrics. ROC is a widely used method to evaluate the performance of VS in distinguishing known actives from decoy compounds (47) . The AUC then quantitatively compares the performance of different receptors; values of 0.5 correspond to a random selection of a compound in the library.
Results and Discussion
Structural flexibility of cis-FPPS, cis-DPPS, and UPPS To explore the conformational flexibility of the active sites of cis-FPPS and cis-DPPS, fluctuations in the volume of the binding pocket during the MD simulations were analyzed for each monomer in the various systems. We begin by considering cis-DPPS, as this is thought to be a key new drug target, while cis-FPPS appears to be non-essential (9).
We show in Figure 3A and 700 A 3 range are subsequently observed, the large range in volumes seen clearly indicating the flexible nature of the active site, the largest volumes likely being related to the need to house the large (C 50 ) cis-DPP product. Interestingly, the presence of the (C 10 ) substrate-like ligand (CITPP, Figure 1B) , a structural analog of GPP, restricts the active site volume to~400 A 3 during the entire simulation ( Figure 3C ), due presumably to strong hydrogen bonding networks and salt bridges between the diphosphate moiety of CITPP and Arg residues, together with hydrophobic interactions in the active site. Figure 4 clearly shows the large volume differences observed between the closed (X-ray) and most open (MD) structures. This arises from a pronounced bend in helix a3 (between residues S126 and F136), which is very similar to what was previously seen in UPPS (48) . This bent helix is present in both the apo cis-DPPS X-ray structure and the CITPP X-ray structure ( Figure 2B ) and corresponds to a small pocket volume. However, as discussed below in more detail, this pocket is too small to accommodate the cis-DPP product, which can, however, be docked to the most open MD structure ( Figure 4B ), and this bend motion is likely to be important in catalysis. Interestingly, we observe a closing of the large pocket during an MD simulation in which we docked CITPP to an open structure ( Figure 5 ). In this simulation, the initial structure had a volume of 756 A 3 ( Figure 5B ), but this rapidly decreased during the simulation as the pocket closed ( Figure 5B and C) with the closed structure having a volume V~230 A 3 . Thus, the substrate-like ligand induces formation of a closed state. Similar effects are also seen with substratelike ligands in UPPS, as described in more detail below, and are important in the context of virtual screening and in catalysis.
Cis-FPPS, producing the C 15 isoprenoid cis-FPP, has not unexpectedly a smaller active site than does cis-DPPS, which synthesizes the C 50 compound, DPP. The active site of cis-FPPS during the MD simulations also remains in a relatively closed state, fluctuating only up to V~480 A 3 , even in the absence of any ligands ( Figure 3D ). In the presence of the small, substrate-like inhibitor CITPP in both monomers, the active site volume (V~300 A 3 ) remains quite constant along the entire trajectory ( Figure 3E ). CIT-PP is a known inhibitor of cis-FPPS, and as with CITPP binding to cis-DPPS ( Figures 3C and 5C ), CITPP stabilizes the closed conformation. With the non-native substrate alltrans-FPP, the active site volume is larger ( Figure 3F ), but again does not approach the much larger volumes seen in apo cis-DPPS.
These results are all of interest in the context of chain length regulation during catalysis, as discussed in more detail in the following sections, as well as in inhibitor discovery.
Pocket volume and principal component analysis of cis-FPPS, DPPS, and UPPS
We next sought to compare the structures of cis-FPPS, cis-DPPS, and UPPS in detail using pocket volume and principal component analyses. Pocket volume results are shown in Table 1 for all three proteins (as well as for Rv3378c), using both X-ray and in some cases, MD results.
For cis-FPPS, the pocket volumes seen in X-ray crystallographic structures are all in the range 240-327 A similar to these found in substrate-like liganded UPPS structures (270-315 A 3 , Table 1 ).
In the most open MD structures, the volumes in cis-FPPS and cis-DPPS increase to 537 A 3 and to 882 A 3 , respectively. These values are more similar to those found in the 'ajar' and open UPPS structures (range 456-1440 A 3 ) but are clearly, on average, smaller-most likely due to the fact that the UPPS structures in many cases have multiple bound ligands (up to 4), while cis-FPPS and cis-DPPS do not. However, it is possible that site 4 in UPPS is not actually involved in catalysis, although it can house potent inhibitors.
An attractive method for structure comparison is to use a principal component analysis (PCA) method as in PCA, there are more parameters to be compared. In previous work on UPPS (7), we found that there were three UPPS clusters in (PC1, PC2) principal component space: closed (substrate-like) structures, 'ajar' (apo and other non-bisphosphonate inhibitor) structures, and open (bisphosphonate inhibitors-often with multiple ligands) structures. As can be seen in Figure 6A , there are 3 main regions in PC space for cis-FPPS, cis-DPPS, and UPPS: A, B, and C, respectively, where the UPPS structures are circled. The B and C clusters ('ajar' and open, respectively) are solely populated by UPPS structures, while the A cluster contains the closed UPPS structures in the circle as well as all of the cis-FPPS and cis-DPPS X-ray structures.
As noted above, the pocket volumes seen (Table 1) in the X-ray structures of cis-DPPS are too small to accommodate a cis-DPP ligand (V = 879 A 3 ), and we were unable to dock cis-DPP to any of the cis-DPPS structures, although we could dock them to the MD structures. We thus next investigate the MD results in more detail. A PCA analysis of the cis-FPPS and cis-DPPS MD trajectories is shown in Figure 6B (cis-FPPS, green dots; cis-DPPS, yellow dots) and clearly shows that a large conformational space is sampled in the simulations-although interestingly the spaces sampled do not quite overlap the UPPS B and C domains, due presumably at least in part to the fact that the UPP is slightly larger than DPP.
With Rv3378c, the pocket volumes for essentially all X-ray structures have V~1000 A 3 (Table S1 ), and the pockets remain quite open, with or without a bound inhibitor (Figure 3G and H). As Rv3378c is not a cis-prenyl synthase but rather a tuberculosinyl adenosine transferase (that happens to have a similar f-fold structure), it appears that a larger pocket may be required here because both substrates are relatively large but additional X-ray structures are needed to probe the Rv3378c mechanism of action in detail.
Chain elongation mechanisms of cis-FPPS, cis-DPPS, and UPPS
The active site volume and PC analysis results described above indicate that the cis-FPPS and cis-DPPS X-ray structures correspond to the closed state of UPPS in which case, certainly with cis-DPPS, it would be impossible to dock in a C 50 product, as we indeed found experimentally (data not shown). We thus next used the Glide program to dock prenyl diphosphates containing from 2 to 12 prenyl groups (i.e., C 10 -C 55 ) to cis-FPPS, cis-DPPS as well as UPPS using the most open (largest volume) MD-based protein structures. Docking poses for the corresponding products are shown in Figure 7A -C, and docking scores as a function of the prenyl chain length (FPP = C 15 ; DPP = C 50 , etc.) are shown in Figure 7D . This approach is similar in spirit to that used by Wallrapp et al. (49) to study docking to trans-prenyl transferases, but here we use MD structures to account for the protein conformational flexibility.
For UPPS (green dots, Figure 7D ), we see an expected 'U-shaped' curve in which the best docking score is found with a C 50 species. The binding energy/docking score becomes slightly worse with an increase in chain length, and C 60 could not be docked. For cis-DPPS, the minimum energy is at C 30 with C 35 slightly higher and C 50 much higher ( Figure 7D higher energy and C 25 higher still. Longer chain species again failed to dock. With cis-DPPS and UPPS, it can be seen that there is no energy minimum at the normal product chain length (C 50 or C 55 ). Rather, with DPPS, the binding energy (Glide score) for C 50 (in DPPS) is~4 kcal/mol higher than with C 30 , while C 55 did not dock. Likewise, with UPPS, the minimum is at C 50 with the C 55 product 1.5 kcal/mol higher, and C 60 did not dock. Clearly, these results indicate that once the chain becomes sufficiently long, its binding energy increases, which results in product being released from the protein. The product ('P') chain lengths are indicated in Figure 7D . With cis-FPPS, the binding energy of the product (C 15 ) is again~3 kcal/mol higher than with C 10 and is about the same as observed with the C 20 species (~À5 kcal/mol), C 25 is a weaker binder, and all longer chain species (C 30 through C 60 ) failed to dock. So, the docking results all indicate that there are significant decreases in the binding energy of products (versus shorter reaction intermediates).
DPPS inhibition and receptor flexibility
We next sought to see to what extent we could use the MD structures in computational docking/virtual screening. As noted above, DPPS (Rv2361c) is an essential gene in M. tuberculosis and converts cis-FPP to cis-DPP (Figure 1A) . Cis-FPPS is, however, not an essential gene, which suggests that GPP (the cis-FPPS substrate) can still be converted to long chain prenyl diphosphates (by cis-DPPS), which can then be used in cell wall biosynthesis. Ideally, then, an inhibitor should inhibit cis-DPPS with either GPP or cis-FPP as substrate. We thus next screened our in-house library of putative prenyl synthase inhibitors against cis-DPPS using GPP, cis-FPP, and trans-FPP (which can also make long chain prenyl diphosphates) as substrates. This resulted in 43 inhibitors with IC 50 values in the 30 nM to 20 lM range ( Figure S1 ) when using GPP as substrate; 19 inhibitors with IC 50 in the 600 nM to~100 lM range when using cis-FPP as substrate ( Figure S2 ), and 53 inhibitors with IC 50 as low as 650 nM using trans-FPP as a substrate.
We first carried out self-docking of the cocrystallized ligand CITPP into our cis-DPPS receptor grid center as a preliminary test of the ability to recover the crystallographic binding pose of the ligand. The docking pose shown in Figure S4 confirmed the validity of this grid center. We also investigated the possibility of the existence of other binding sites in DPPS using FTMap (50) . The results of the FTMap analysis shown in Figure S5 suggest that DPPS does not have other binding sites. Therefore, we next proceeded to perform virtual screens (VSs) with the grid center located at the native binding site.
We evaluated VS receptor performance using the receiver operating characteristic (ROC) and area under the curve (AUC) metrics (47) . AUC results using GPP as substrate are shown in Figures 8A and S6 ; for a cis-FPP substrate, in Figures 8B and S7; and for a trans-FPP substrate, in Figures 8C and S8 . The populations of the apo DPPS MD structures ( Figure 8 ) are in red and show that the most probable receptor volume is~250 A 3 . In the case of GPP as substrate, the AUC results ( Figure 8A , in blue; Figure  S6 ) show that the top scoring receptors all have volumes a 300 A 3 . This cutoff is more pronounced when cis-FPP is used as the substrate ( Figure 8B , in blue; Figure S7 ) where there is clearly a step-function behavior: Receptors with V b 300 A 3 have no predictive power in selecting actives from decoys, while 90% of receptors having V > 300 A 3 have AUC > 0.5 with the best receptors from the MD trajectory having AUC~0.7, a considerable enrichment in actives. The reason for the presence of some enrichment at V < 300 A 3 with GPP as substrate, while speculative, may be that the initial step in GPP chain elongation is being targeted by an inhibitor (which can bind to a smaller receptor pocket), while with cis-FPP as substrate, the normal chain elongation step is being targeted. In any case, with both systems, neither the most populated conformations nor any X-ray crystallographic receptors provided high predictive performance. The best performances with cis-FPP, the normal substrate, were observed with receptors 10, With trans-FPP ( Figures 8C and S8) as substrate, we found several of the smaller receptors performed well, a result that can be attributed to the larger number of small (bisphosphonate) inhibitors present in this subset of our screening library (compound structures are shown in Figure S3) .
Overall, the ROC-AUC results clearly show that there are large enrichments of cis-DPPS actives possible using the MD-based structures, most of which are very rarely sampled, while the most frequently sampled conformations do not provide such enrichment as in many cases, the sizes of the inhibitors are larger than the most frequently sampled pocket volumes. 
Toward multitargeting of cis-FPPS, cis-DPPS, and Rv3378c
In previous work (11), we reported the X-ray crystallographic structure of Rv3378c in the presence of its substrate, tuberculosinyl diphosphate, as well as in the presence of an inhibitor, the bisphosphonate BPH-629 ( Figure 1B) . Bisphosphonates are often found to be good inhibitors of prenyl synthases as they contain a diphosphate group isostere, a bisphosphonate. For example, bisphosphonates are known potent inhibitors of UPPS as well as trans-FPPS (the latter inhibitors being used clinically to treat bone resorption diseases). However, there has been little progress in developing bisphosphonates that kill bacteria as they do not penetrate the bacterial cell wall. However, there are many other UPPS inhibitors known, and many of the cis-DPPS inhibitors shown in Figure S1 also inhibit UPPS (7). We thus tested several of these ( Figure S9 ) for activity against cis-FPPS and three ( Figure S10 ) for activity against Rv3378c (using tuberculosinyl diphosphate and adenosine as substrates). The most potent inhibitor against Rv3378c was BPH-629, which had an IC 50 of 210 nM (and an IC 50 of 610 nM against DPPS, using cis-FPP as substrate). However, BPH-629 was inactive against the M. tuberculosis model, M. smegmatis. In contrast, the bisamidine BPH-1417 ( Figure 1B) had an IC 50 = 0.5-20 lM, depending on substrate against DPPS as well as an IC 50 = 660 nM against Rv3378c. In addition, it also inhibited cis-FPPS ( Figure S9 ) with an IC 50 that in each case, the substrate site, that is, site 1, is likely to be occupied.
In previous work (7), we showed that the bisamidine BPH-1358 ( Figure S11 ) was a potent UPPS inhibitor that also had in vivo activity in a S. aureus mouse model of infection (7), but BPH-1358 was inactive here against Rv3378c. However, the bisamidine BPH-1417 has potent in vitro as well as in vivo activity against S. aureus and has also been reported to have an MIC in the 0.3-1.3 lg/mL range against M. tuberculosis (51). It is likely that DNA is also a target in these organisms (as with other bisamidines), and the ability to potentially target DNA, cell wall biosynthesis (cis-FPPS/cis-DPPS), and virulence factor formation (Rv3378c) is clearly of interest in the context of multitarget inhibitor development (52) for drug-resistant infections.
Conclusions
In this work, we carried out MD simulations of three prenyl synthase enzymes from M. tuberculosis: cis-FPPS (Rv1086c); cis-DPPS (Rv2361c); and tuberculosinol/tuberculosinyl adenosine synthase (Rv3378c), proteins which all contain a f-fold structure with cis-DPPS and Rv3378c being of interest as new tuberculosis drug targets. Cis-DPPS exhibited large active site pocket volume fluctuations in its apo and IPP-bound forms, but not in the presence of the substrate-like inhibitor, CITPP. The largest volume was V = 882 A 3 , very close to that of the cis-DPP product (V = 879 A 3 ). With cis-FPPS, the volumes were as expected much smaller but increased to up to~537 A 3 in the MD simulation. For UPPS, the largest pocket volume in MD is 1032 A 3 , close to the volume of UPP (V~965 A 3 ). We used the FPPS, DPPS, and UPPS MD structures to examine the chain length dependence of ligand binding energies using C 10 -C 60 prenyl diphosphates, to help elucidate chain length regulation mechanisms. The most favorable binding energies were found with compounds having chain lengths shorter than the products, where energies were % 3 kcal/mol higher than the lowest energies seen. Chains that were~>2 prenyls longer than products either did not dock or had very poor docking scores. We then used a PCA method to analyze the X-ray structures of cis-FPPS, cis-DPPS, and UPPS, together with results from cis-FPPS and cis-DPPS MD trajectories. The FPPS/DPPS structures clustered most closely with closed (substrate-like liganded) UPPS structures, presumably because many (open or ajar) UPPS structures have multiple bound ligands, while cis-FPPS and cis-DPPS do not. That is, the UPPS structures do not necessarily mimic normal productbound structures (as evidenced also by their pocket volumes which in many cases are considerably larger than the UPP product volume). Finally, we investigated the inhibition of cis-DPPS by a range of putative prenyl transferase inhibitors, finding several potent leads. Using these results, we found using the ROC-AUC method that MD-based structures with receptor volumes >300 A 3 , in general, gave the best ROC-AUC values (~0.7). We also tested several of the cis-DPPS inhibitors for activity against cis-FPPS and Rv3378c. Bisphosphonates and bisamidines had activity against several targets, the best being BPH-1417 which was a 660-nM inhibitor of Rv3378c, a 4.8-lM inhibitor of cis-FPPS, and a 1.3-lM inhibitor of cis-DPPS, results that open up the possibility of multitarget inhibition in which both cell wall biosynthesis and virulence factor formation may be inhibited. 
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